-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 De0v1wv6tdReWlilGe9Zwbouc3EHU76VZvGxMKx3yddzb+hvmUw29+6kfZXo/WSO
 +iNJ8BUhSwDGHS2VaHQ8Kg==

<SEC-DOCUMENT>0001019687-06-001702.txt : 20060720
<SEC-HEADER>0001019687-06-001702.hdr.sgml : 20060720
<ACCEPTANCE-DATETIME>20060719190413
ACCESSION NUMBER:		0001019687-06-001702
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060718
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20060720
DATE AS OF CHANGE:		20060719

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		06970249

	BUSINESS ADDRESS:	
		STREET 1:		7825 FAY AVENUE SUITE 200
		CITY:			LAJOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		2129120930

	MAIL ADDRESS:	
		STREET 1:		7825 FAY AVENUE SUITE 200
		CITY:			LAJOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k-071906.txt
<TEXT>
<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934



Date of Report (Date of earliest event reported):   July 18, 2006
                                                    ----------------------------


                              AETHLON MEDICAL, INC.
             (Exact name of registrant as specified in its charter)

            Nevada                       0-21846                 13-3632859
- ------------------------------- -------------------------- ---------------------
 (State or other jurisdiction    (Commission File Number)     (IRS Employer
      of incorporation)                                     Identification No.)

 3030 Bunker Hill Street, Suite 4000, San Diego, California         92109
- ------------------------------------------------------------- ------------------
             (Address of principal executive offices)            (Zip Code)


Registrant's telephone number, including area code: (858) 459-7800
                                                    ----------------------------


                                 Not applicable
- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))

<PAGE>


THIS FORM 8-K AND OTHER REPORTS FILED BY AETHLON MEDICAL, INC. (THE "COMPANY")
FROM TIME TO TIME WITH THE SECURITIES AND EXCHANGE COMMISSION (COLLECTIVELY THE
"FILINGS") CONTAIN FORWARD LOOKING STATEMENTS AND INFORMATION THAT ARE BASED
UPON BELIEFS OF, AND INFORMATION CURRENTLY AVAILABLE TO, THE COMPANY'S
MANAGEMENT AS WELL AS ESTIMATES AND ASSUMPTIONS MADE BY THE COMPANY'S
MANAGEMENT. WHEN USED IN THE FILINGS THE WORDS "ANTICIPATE", "BELIEVE",
"ESTIMATE", "EXPECT", "FUTURE", "INTEND", "PLAN" OR THE NEGATIVE OF THESE TERMS
AND SIMILAR EXPRESSIONS AS THEY RELATE TO THE COMPANY'S OR THE COMPANY'S
MANAGEMENT IDENTIFY FORWARD LOOKING STATEMENTS. SUCH STATEMENTS REFLECT THE
CURRENT VIEW OF THE COMPANY WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO
RISKS, UNCERTAINTIES, ASSUMPTIONS AND OTHER FACTORS RELATING TO THE COMPANY'S
INDUSTRY, OPERATIONS AND RESULTS OF OPERATIONS AND ANY BUSINESSES THAT MAY BE
ACQUIRED BY THE COMPANY. SHOULD ONE OR MORE OF THESE RISKS OR UNCERTAINTIES
MATERIALIZE, OR SHOULD THE UNDERLYING ASSUMPTIONS PROVE INCORRECT, ACTUAL
RESULTS MAY DIFFER SIGNIFICANTLY FROM THOSE ANTICIPATED, BELIEVED, ESTIMATED,
EXPECTED, INTENDED OR PLANNED.


ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF PRINCIPAL OFFICERS.

          On July 18, 2006, Mr. Harold H. Handley was appointed as President of
the Company. Mr. Handley brings over 20 years experience in management and
research in immunology, biotechnology and medical devices. Mr. Handley has
authored or co-authored over 20 publications and helped developed 15 patents.
Prior to joining Aethlon, Mr. Handley was Executive Vice President and Chief
Scientific Officer for Transvivo, Inc., a privately-held company, from 2000 to
2006. From 1996 to 2000, Mr. Handley was Vaccine Program Director for Maxim
Pharmaceuticals, Inc. Mr. Handley was a co-founder of Idec Limited Partners,
Inc., today known as Biogen Idec, Inc., operating with a market value exceeding
$14 billion. (NasdaqGS:BIIB). Mr. Handley holds a Ph.D in Anatomy and Cell
Biology from University of Virginia and a B.A. in Zoology from the University of
California, Los Angeles. Mr. Handley will receive a salary of $180,000 per year
and stock options to purchase 500,000 shares of the Company's common stock at an
exercise price of $0.28 per share vesting over three years. With Mr. Handley's
appointment, Mr. James A. Joyce resigned as President of the Company. Mr. Joyce
will continue to serve as Chief Executive Officer and Chairman of the Board of
Directors.

         On July 18, 2006, the Company issued a press release announcing the
appointment of Mr. Handley as the Company's President. The full text of the
press release is set forth in Exhibit 99.1 attached hereto and is incorporated
in this Report as if fully set forth herein.


ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

          99.1      Press Release dated July 18, 2006


                                       2

<PAGE>

                                   SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                                        AETHLON MEDICAL, INC.
                                                    ----------------------------
                                                            (Registrant)

Date     July 19, 2006
      ----------------------
                                         By: /s/ James Dorst
                                             -----------------------------------
                                       Name: James Dorst
                                             -----------------------------------
                                      Title: Chief Financial Officer
                                             -----------------------------------


                                       3
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_8ke99-1.txt
<DESCRIPTION>PRESS RELEASE DATED JULY 18, 2006
<TEXT>
<PAGE>

EXHIBIT 99.1

[AETHLON LOGO]


FOR IMMEDIATE RELEASE:                           Contact:

                                                 Jeff Richardson
                                                 Senior Director, Communications
                                                 858.459.7800 x302
                                                 jrichardson@aethlonmedical.com


                                                 James A. Joyce
                                                 Chairman, CEO
                                                 858.459.7800 x301
                                                 jj@aethlonmedical.com


         DR. HAROLD HANDLEY APPOINTED PRESIDENT OF AETHLON MEDICAL, INC.


San Diego, CA, July 18, 2006 -Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in
developing therapeutic devices for infectious disease, announced today that
Harold ("Hal") H. Handley, Jr. Ph.D. has been appointed President of the
organization. Dr. Handley has over 20 years of management and research
experience and was a co-founder of Idec Limited Partners, Inc., today known as
Biogen Idec, Inc., operating with a market value exceeding $14 billion. Dr
Handley has authored numerous scientific publications and is the primary
inventor of more than twelve issued patents. Most recently, Dr. Handley was
Executive Vice President and Chief Scientific Officer of Transvivo, Inc., a
developer of biofiltration and catheter devices, where he oversaw all
regulatory, clinical, patent, and research efforts.

"I believe Aethlon has established a scientific vision that could provide
medical benefit to large numbers of civilian and military personnel," stated Dr.
Handley. "I'm excited to participate in the effort to commercialize the
HemopurifierTM, and look forward to developing other potentially valuable
therapeutics," concluded Handley.

As President, Dr. Handley will be responsible for the management of regulatory
initiatives, new product development, coordination of grant proposals and
science publications, and related communications to the medical community.

 "Hal is a tremendous addition to our team," stated Aethlon Chairman and CEO,
James A. Joyce. "Especially when considering our near-term plans to file
regulatory submissions with the FDA, and the continued testing of the
Hemopurifier that is expected abroad." "Over the last year, we have assembled a
team that is capable of executing our current scientific initiatives and
beyond," concluded Joyce, who previously held the position of President in
addition to his role as Chairman and CEO.

ABOUT AETHLON MEDICAL
- ---------------------

Aethlon Medical is developing the first medical device to treat infectious
disease. The device, known as the Hemopurifier(TM), is a broad-spectrum
treatment countermeasure against drug and vaccine resistant bioweapons,
naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic
infectious disease targets including Hepatitis-C (HCV) and the Human
Immunodeficiency Virus (HIV). Global researcher, Frost & Sullivan, recently
awarded the HemopurifierTM the 2006 TECHNOLOGY INNOVATION AWARD for its advances
in the field of biodefense. Aethlon has also initiated research on a second
generation HemopurifierTM that targets the capture of growth factors inherent in
the spread of Cancer. More information on Aethlon Medical and the HemopurifierTM
technology can be found at www.aethlonmedical.com.




CERTAIN OF THE STATEMENTS HEREIN MAY BE FORWARD-LOOKING AND INVOLVE RISKS AND
UNCERTAINTIES. SUCH FORWARD-LOOKING STATEMENTS INVOLVE ASSUMPTIONS, KNOWN AND
UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL
RESULTS, PERFORMANCE OR ACHIEVEMENTS OF AETHLON MEDICAL, INC TO BE MATERIALLY
DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE, OR ACHIEVEMENTS EXPRESSED OR
IMPLIED BY THE FORWARD-LOOKING STATEMENTS. SUCH POTENTIAL RISKS AND
UNCERTAINTIES INCLUDE, WITHOUT LIMITATION, THE COMPANY'S ABILITY TO RAISE
CAPITAL WHEN NEEDED, THE COMPANY'S ABILITY TO COMPLETE THE DEVELOPMENT OF ITS
PLANNED PRODUCTS, THE ABILITY OF THE COMPANY TO OBTAIN FDA AND OTHER REGULATORY
APPROVALS PERMITTING THE SALE OF ITS PRODUCTS, THE COMPANY'S ABILITY TO
MANUFACTURE ITS PRODUCTS AND PROVIDE ITS SERVICES, THE IMPACT OF GOVERNMENT
REGULATIONS, PATENT PROTECTION ON THE COMPANY'S PROPRIETARY TECHNOLOGY, PRODUCT
LIABILITY EXPOSURE, UNCERTAINTY OF MARKET ACCEPTANCE, COMPETITION, TECHNOLOGICAL
CHANGE, AND OTHER RISK FACTORS. IN SUCH INSTANCES, ACTUAL RESULTS COULD DIFFER
MATERIALLY AS A RESULT OF A VARIETY OF FACTORS, INCLUDING THE RISKS ASSOCIATED
WITH THE EFFECT OF CHANGING ECONOMIC CONDITIONS AND OTHER RISK FACTORS DETAILED
IN THE COMPANY'S SECURITIES AND EXCHANGE COMMISSION FILINGS.

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
